LeonardBSaltzMD

Professor of Medicine, Cornell University-Weill Medical College

Overview of Dr. Saltz

Dr. Leonard Saltz is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Yale School of Medicine and has been in practice 34 years. Dr. Saltz accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 64 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(206) 451-7956

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1983 - 1986
Yale School of MedicineClass of 1983

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2020 - 2025
NY State Medical License 1985 - 2025
PA State Medical License 2023 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Irinotecan in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 1998 Jun 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Cancer Start of enrollment: 1999 Apr 01
Completed
Phase 1
Irinotecan in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Aug 01
Completed
Phase 1
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Start of enrollment: 2000 Apr 01
Completed
Phase 1
Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer Start of enrollment: 2001 Feb 01
Completed
Phase 2
Cetuximab in Treating Patients With Stage IV Colorectal Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 2
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Start of enrollment: 2001 Mar 01
Completed
Phase 2
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 2001 Jun 01
Completed
Phase 1, Phase 2
Pyroxamide in Treating Patients With Advanced Cancer Start of enrollment: 2002 Apr 01
Completed
Phase 1
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2002 Aug 01
Completed
Phase 1, Phase 2
Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer Start of enrollment: 2003 Dec 01
Completed
Phase 2
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer Start of enrollment: 2004 Mar 01
Completed
Not Applicable
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 3
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Start of enrollment: 2007 Mar 01
Completed
Not Applicable
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Start of enrollment: 2008 Jan 01
Completed
Phase 2
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer Start of enrollment: 2009 Feb 01
Terminated
Not Applicable
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Start of enrollment: 2009 May 01
Completed
Phase 2
Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer Start of enrollment: 2009 Jun 01
Completed
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer Start of enrollment: 2010 Aug 01
Terminated
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. Start of enrollment: 2013 Sep 01
Completed
Phase 1
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors Start of enrollment: 2013 Nov 19
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Evaluating the utility ofpromoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance).
Elizabeth S Nakasone, Tyler J Zemla, Ming Yu, She Yu Lin, Fang-Shu Ou
Epigenetics. 2024-12-01
ASO Visual Abstract: Outcomes of Distal Rectal Cancer Patients Who Did Not Qualify for Watch-and-Wait-Comparison of Intersphincteric Resection Versus Abdominoperineal ...
Yael Feferman, Floris S Verheij, Hannah Williams, Dana M Omer, Emmanouil P Pappou
Annals of Surgical Oncology. 2024-11-04
Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy.
Sean J Judge, Parisa Malekzadeh, Marina J Corines, Marc J Gollub, Natally Horvat
Journal of the National Cancer Institute. 2024-11-01

Journal Articles

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19
Mark J Ratain, Leonard B Saltz, JAMA Oncology
Pelvic MRI After Induction Chemotherapy and Before Long-Course Chemoradiation Therapy for Rectal Cancer: What Are the Imaging Findings?
Andrea Cercek, Leonard Saltz, Marc J Gollub, Patricio Lynn, Martin R Weiser, European Radiology

Lectures

Value Propositions in Colorectal Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Counterpoint: We Need to be Highly Selective in the Patients We Test
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Selected Updates in Colorectal Cancer
2007 Annual Meeting, Chicago, Illinois, USA

Authored Content

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19May 2020

Press Mentions

Pre-Op Aflibercept Ups Response in High-Risk Rectal CancerAugust 29th, 2019
Combo Immunotherapy Failed to Improve Outcomes in MSS Colorectal CancerApril 30th, 2019
Dr. Saltz Discusses Chemotherapy in Metastatic CRCDecember 12th, 2017
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment